Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Aikaterini Gkoufa, Eleni Maneta, Georgios N Ntoumas, Vasiliki E Georgakopoulou, Athina Mantelou, Stelios Kokkoris, Christina Routsi
BACKGROUND: In the context of the Coronavirus disease 2019 (COVID-19) pandemic, it has been reported that elderly patients are particularly at risk of developing severe illness and exhibiting increased mortality. While many studies on hospitalized elderly patients with COVID-19 have been published, limited information is available on the characteristics and clinical outcomes of those elderly patients admitted to intensive care unit (ICU). AIM: To review the available evidence of the clinical data of elderly patients admitted to the ICU due to COVID-19...
September 9, 2021: World Journal of Critical Care Medicine
#2
REVIEW
Nwonukwuru Amadi, Radhika Trivedi, Nasim Ahmed
According to the World Health Organization as of September 16, 2021, there have been over 226 million documented cases of coronavirus disease 2019 (COVID-19), which has resulted in more than 4.6 million deaths and approximately 14% develop a more severe disease that requires respiratory assistance such as intubation. Early tracheostomy is recommended for patients that are expected to be on prolonged mechanical ventilation; however, supporting data has not yet been provided for early tracheostomies in COVID-19 patients...
November 9, 2021: World Journal of Critical Care Medicine
#3
JOURNAL ARTICLE
Theodoros Karampitsakos, Elli Malakounidou, Ourania Papaioannou, Vasilina Dimakopoulou, Eirini Zarkadi, Matthaios Katsaras, Panagiota Tsiri, Georgios Tsirikos, Vasiliki Georgiopoulou, Ioanna Oikonomou, Christos Davoulos, Dimitrios Velissaris, Fotios Sampsonas, Markos Marangos, Karolina Akinosoglou, Argyris Tzouvelekis
BACKGROUND: Data on the safety and efficacy profile of tocilizumab in patients with severe COVID-19 needs to be enriched. METHODS: In this open label, prospective study, we evaluated clinical outcomes in consecutive patients with COVID-19 and PaO2 /FiO2 < 200 receiving tocilizumab plus usual care versus usual care alone. Tocilizumab was administered at the time point that PaO2 /FiO2 < 200 was observed. The primary outcome was 28-day mortality. Secondary outcomes included time to discharge, change in PaO2 /FiO2 at day 5 and change in WHO progression scale at day 10...
December 22, 2021: Respiratory Research
#4
REVIEW
Sampath Weerakkody, Pietro Arina, James Glenister, Sam Cottrell, Giacomo Boscaini-Gilroy, Mervyn Singer, Hugh E Montgomery
Non-invasive respiratory support (NIRS) has increasingly been used in the management of COVID-19-associated acute respiratory failure, but questions remain about the utility, safety, and outcome benefit of NIRS strategies. We identified two randomised controlled trials and 83 observational studies, compromising 13 931 patients, that examined the effects of NIRS modalities-high-flow nasal oxygen, continuous positive airway pressure, and bilevel positive airway pressure-on patients with COVID-19. Of 5120 patients who were candidates for full treatment escalation, 1880 (37%) progressed to invasive mechanical ventilation and 3658 of 4669 (78%) survived to study end...
February 2022: Lancet Respiratory Medicine
#5
REVIEW
Jean-Louis Vincent, Marcel Levi, Beverley J Hunt
A proportion of people infected with SARS-CoV-2 develop moderate or severe COVID-19, with an increased risk of thromboembolic complications. The inflammatory response to SARS-CoV-2 infection can cause an acute-phase response and endothelial dysfunction, which contribute to COVID-19-associated coagulopathy, the clinical and laboratory features of which differ in some respects from those of classic disseminated intravascular coagulation. Understanding of the pathophysiology of thrombosis in COVID-19 is needed to develop approaches to management and prevention, with implications for short-term and long-term health outcomes...
February 2022: Lancet Respiratory Medicine
#6
JOURNAL ARTICLE
Zelalem Temesgen, Charles D Burger, Jason Baker, Christopher Polk, Claudia R Libertin, Colleen F Kelley, Vincent C Marconi, Robert Orenstein, Victoria M Catterson, William S Aronstein, Cameron Durrant, Dale Chappell, Omar Ahmed, Gabrielle Chappell, Andrew D Badley
BACKGROUND: The pathophysiology of COVID-19 includes immune-mediated hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is among cytokines that contribute to the inflammatory processes. Lenzilumab, a GM-CSF neutralising monoclonal antibody, was investigated in the LIVE-AIR trial to assess its efficacy and safety in treating COVID-19 beyond available treatments. METHODS: In LIVE-AIR, a phase 3, randomised, double-blind, placebo-controlled trial, hospitalised adult patients with COVID-19 pneumonia not requiring invasive mechanical ventilation were recruited from 29 sites in the USA and Brazil and were randomly assigned (1:1) to receive three intravenous doses of lenzilumab (600 mg per dose) or placebo delivered 8 h apart...
December 1, 2021: Lancet Respiratory Medicine
#7
REVIEW
Prashant Nasa, Elie Azoulay, Arunaloke Chakrabarti, Jigeeshu V Divatia, Ravi Jain, Camilla Rodrigues, Victor D Rosenthal, Waleed Alhazzani, Yaseen M Arabi, Jan Bakker, Matteo Bassetti, Jan De Waele, George Dimopoulos, Bin Du, Sharon Einav, Laura Evans, Simon Finfer, Claude Guérin, Naomi E Hammond, Samir Jaber, Ruth M Kleinpell, Younsuck Koh, Marin Kollef, Mitchell M Levy, Flavia R Machado, Jordi Mancebo, Ignacio Martin-Loeches, Mervyn Mer, Michael S Niederman, Paolo Pelosi, Anders Perner, John V Peter, Jason Phua, Lise Piquilloud, Mathias W Pletz, Andrew Rhodes, Marcus J Schultz, Mervyn Singer, Jéan-François Timsit, Balasubramanian Venkatesh, Jean-Louis Vincent, Tobias Welte, Sheila N Myatra
During the current COVID-19 pandemic, health-care workers and uninfected patients in intensive care units (ICUs) are at risk of being infected with SARS-CoV-2 as a result of transmission from infected patients and health-care workers. In the absence of high-quality evidence on the transmission of SARS-CoV-2, clinical practice of infection control and prevention in ICUs varies widely. Using a Delphi process, international experts in intensive care, infectious diseases, and infection control developed consensus statements on infection control for SARS-CoV-2 in an ICU...
March 2022: Lancet Infectious Diseases
#8
JOURNAL ARTICLE
Jan-Hendrik Naendrup, Jorge Garcia Borrega, Dennis Alexander Eichenauer, Alexander Shimabukuro-Vornhagen, Matthias Kochanek, Boris Böll
BACKGROUND: Reactivation of viruses such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV) are common in critically ill patients and have been described in patients with severe COVID-19. However, it is unclear whether these reactivations are associated with increased mortality and whether targeted treatments are beneficial. METHODS: In a retrospective single-center cohort study, patients with severe COVID-19 treated on our intensive care unit (ICU) were screened for EBV and CMV reactivation as detected by polymerase chain reaction...
November 18, 2021: Journal of Intensive Care Medicine
#9
MULTICENTER STUDY
Kais Al-Abani, Naima Kilhamn, Eva Maret, Johan Mårtensson
Thrombosis and bleeding after implementation of an intermediate-dose prophylactic anticoagulation protocol in intensive care unit (ICU) patients with coronavirus disease 2019 (COVID-19): a multicenter screening study Background: Venous thromboembolism (VTE) is common among critically ill patients with COVID-19. Information regarding VTE prevalence and bleeding complications after implementation of intermediate-dose prophylactic anticoagulation in such patients is, however, limited. Methods: We performed a prospective, observational study in 6 ICUs in 2 university-affiliated teaching hospitals in Sweden...
April 2022: Journal of Intensive Care Medicine
#10
RANDOMIZED CONTROLLED TRIAL
Luis Patricio Maskin, Ignacio Bonelli, Gabriel Leonardo Olarte, Fernando Palizas, Agostina E Velo, María Fernanda Lurbet, Pablo Lovazzano, Sophia Kotsias, Shiry Attie, Ignacio Lopez Saubidet, Natalio D Baredes, Mariano Setten, Pablo Oscar Rodriguez
OBJECTIVE: To determine whether high-dose dexamethasone increases the number of ventilator-free days (VFD) among patients with acute respiratory distress syndrome (ARDS) caused by COVID-19. DESIGN: Multicenter, randomized, open-label, clinical trial. PARTICIPANTS: Consecutive patients with confirmed COVID-19-related ARDS were enrolled from June 17, 2020, to March 27, 2021, in four intensive care units (ICUs) in Argentina. INTERVENTION: 16 mg of dexamethasone intravenously daily for five days followed by 8 mg of dexamethasone daily for five days or 6 mg of dexamethasone intravenously daily for 10 days...
April 2022: Journal of Intensive Care Medicine
#11
JOURNAL ARTICLE
Shan Wang, Christy Huynh, Shahidul Islam, Brian Malone, Naveed Masani, D'Andrea Joseph
PURPOSE: Safety of remdesivir in patients with renal impairment is unknown. Incidence of liver injury secondary to remdesivir is also unknown. The objective of this study is to assess the incidence of acute kidney injury (AKI) and to trend the liver enzymes during remdesivir treatment and change in eGFR from baseline to end of treatment as well as 48 h post completion of remdesivir therapy. METHODS: This is a retrospective chart review study including adult patients admitted with COVID-19 receiving remdesivir with a baseline eGFR < 30 ml/min per 1...
December 30, 2021: Journal of Intensive Care Medicine
#12
JOURNAL ARTICLE
Karanvir Kaushal, Hardeep Kaur, Phulen Sarma, Anusuya Bhattacharyya, Dibya Jyoti Sharma, Manisha Prajapat, Mona Pathak, Ashish Kothari, Subodh Kumar, Satyavati Rana, Manpreet Kaur, Ajay Prakash, Anissa Atif Mirza, Prasan Kumar Panda, S Vivekanandan, Balram Ji Omar, Bikash Medhi, Manisha Naithani
Ferritin is a known inflammatory biomarker in COVID-19. However, many factors and co-morbidities can confound the level of serum ferritin. This current metaanalysis evaluates serum ferritin level in different severity levels in COVID-19. Studies evaluating serum ferritin level in different clinical contexts (COVID-19 vs. control, mild to moderate vs. severe to critical, non-survivor vs. survivor, organ involvement, ICU and mechanical ventilation requirement) were included (total 9 literature databases searched)...
February 2022: Journal of Critical Care
#13
MULTICENTER STUDY
Jan-Paul Roozeman, Guido Mazzinari, Ary Serpa Neto, Markus W Hollmann, Frederique Paulus, Marcus J Schultz, Luigi Pisani
BACKGROUND: The SpO2 /FiO2 is a useful oxygenation parameter with prognostic capacity in patients with ARDS. We investigated the prognostic capacity of SpO2 /FiO2 for mortality in patients with ARDS due to COVID-19. METHODS: This was a post-hoc analysis of a national multicenter cohort study in invasively ventilated patients with ARDS due to COVID-19. The primary endpoint was 28-day mortality. RESULTS: In 869 invasively ventilated patients, 28-day mortality was 30...
April 2022: Journal of Critical Care
#14
JOURNAL ARTICLE
S Brinkman, F Termorshuizen, D A Dongelmans, F Bakhshi-Raiez, M S Arbous, D W de Lange, N F de Keizer
PURPOSE: Describe the differences in characteristics and outcomes between COVID-19 and other viral pneumonia patients admitted to Dutch ICUs. MATERIALS AND METHODS: Data from the National-Intensive-Care-Evaluation-registry of COVID-19 patients admitted between February 15th and January 1th 2021 and other viral pneumonia patients admitted between January 1st 2017 and January 1st 2020 were used. Patients' characteristics, the unadjusted, and adjusted in-hospital mortality were compared...
December 17, 2021: Journal of Critical Care
#15
RANDOMIZED CONTROLLED TRIAL
Gustavo A Ospina-Tascón, Luis Eduardo Calderón-Tapia, Alberto F García, Virginia Zarama, Freddy Gómez-Álvarez, Tatiana Álvarez-Saa, Stephania Pardo-Otálvaro, Diego F Bautista-Rincón, Mónica P Vargas, José L Aldana-Díaz, Ángela Marulanda, Alejandro Gutiérrez, Janer Varón, Mónica Gómez, María E Ochoa, Elena Escobar, Mauricio Umaña, Julio Díez, Gabriel J Tobón, Ludwig L Albornoz, Carlos Augusto Celemín Flórez, Guillermo Ortiz Ruiz, Eder Leonardo Cáceres, Luis Felipe Reyes, Lucas Petri Damiani, Alexandre B Cavalcanti
IMPORTANCE: The effect of high-flow oxygen therapy vs conventional oxygen therapy has not been established in the setting of severe COVID-19. OBJECTIVE: To determine the effect of high-flow oxygen therapy through a nasal cannula compared with conventional oxygen therapy on need for endotracheal intubation and clinical recovery in severe COVID-19. DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label clinical trial conducted in emergency and intensive care units in 3 hospitals in Colombia...
December 7, 2021: JAMA
#16
RANDOMIZED CONTROLLED TRIAL
Anders Granholm, Marie Warrer Munch, Sheila Nainan Myatra, Bharath Kumar Tirupakuzhi Vijayaraghavan, Maria Cronhjort, Rebecka Rubenson Wahlin, Stephan M Jakob, Luca Cioccari, Maj-Brit Nørregaard Kjær, Gitte Kingo Vesterlund, Tine Sylvest Meyhoff, Marie Helleberg, Morten Hylander Møller, Thomas Benfield, Balasubramanian Venkatesh, Naomi E Hammond, Sharon Micallef, Abhinav Bassi, Oommen John, Vivekanand Jha, Klaus Tjelle Kristiansen, Charlotte Suppli Ulrik, Vibeke Lind Jørgensen, Margit Smitt, Morten H Bestle, Anne Sofie Andreasen, Lone Musaeus Poulsen, Bodil Steen Rasmussen, Anne Craveiro Brøchner, Thomas Strøm, Anders Møller, Mohd Saif Khan, Ajay Padmanaban, Jigeeshu Vasishtha Divatia, Sanjith Saseedharan, Kapil Borawake, Farhad Kapadia, Subhal Dixit, Rajesh Chawla, Urvi Shukla, Pravin Amin, Michelle S Chew, Christian Aage Wamberg, Christian Gluud, Theis Lange, Anders Perner
PURPOSE: We compared dexamethasone 12 versus 6 mg daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia in the international, randomised, blinded COVID STEROID 2 trial. In the primary, conventional analyses, the predefined statistical significance thresholds were not reached. We conducted a pre-planned Bayesian analysis to facilitate probabilistic interpretation. METHODS: We analysed outcome data within 90 days in the intention-to-treat population (data available in 967 to 982 patients) using Bayesian models with various sensitivity analyses...
January 2022: Intensive Care Medicine
#17
JOURNAL ARTICLE
Maria Andersson, Anna Nordin, Åsa Engström
AIM: The aim of the study was to deductively study person-centred care, based on critical care nurses' experiences during the first phase of the CoViD-19 pandemic. DESIGN: The study used a qualitative design. METHOD: Data collection was conducted as individual interviews and was analysed with qualitative content analysis with a deductive approach. PARTICIPANTS: Six critical care nurses working in a special CoViD-19 intensive care unit during the first phase of the pandemic participated...
November 17, 2021: Intensive & Critical Care Nursing: the Official Journal of the British Association of Critical Care Nurses
#18
JOURNAL ARTICLE
Alberto Lucchini, Vincenzo Russotto, Nicola Barreca, Marta Villa, Giulia Casartelli, Yelenia Marcolin, Barbara Zyberi, Domenico Cavagnuolo, Giacomo Verzella, Roberto Rona, Roberto Fumagalli, Giuseppe Foti
OBJECTIVE: To investigate short and long-term complications due to standard (≤24 hours) and extended (>24 hours) prone position in COVID-19 patients. METHODS: Retrospective cohort study conducted in an Italian general intensive care unit. We enrolled patients on invasive mechanical ventilation and treated with prone positioning. We recorded short term complications from the data chart and long-term complications from the scheduled follow-up visit, three months after intensive care discharge...
October 29, 2021: Intensive & Critical Care Nursing: the Official Journal of the British Association of Critical Care Nurses
#19
JOURNAL ARTICLE
Alyson Keen, Annie George, B T Stuck, Colby Snyder, Kyle Fleck, Jose Azar, Areeba Kara
OBJECTIVE: Stress among family members of hospitalised intensive care unit patients may be amplified in the context of a global pandemic and strict visitor restrictions. A nurse family liaison role in the COVID-19 units was implemented to serve as a connection between the care team and a designated family member. Our objective was to describe the experience of a nurse family liaison role implemented during the COVID-19 pandemic from the perspective of nurses who functioned in the liaison role and intensive care nurses who worked with the liaisons...
December 3, 2021: Intensive & Critical Care Nursing: the Official Journal of the British Association of Critical Care Nurses
#20
REVIEW
Megan L Crichton, Pieter C Goeminne, Krizia Tuand, Thomas Vandendriessche, Thomy Tonia, Nicolas Roche, James D Chalmers
Hospitalised patients with coronavirus disease 2019 (COVID-19) have a high mortality rate. There are an increasing number of published randomised controlled trials for anti-inflammatory, anti-viral and other treatments. The European Respiratory Society Living Guidelines for the Management of Hospitalised Adults with COVID-19 were published recently, providing recommendations on appropriate pharmacotherapy.Patient, Intervention, Comparator and Outcomes questions for key interventions were identified by an international panel and systematic reviews were conducted to identify randomised controlled trials meeting the inclusion criteria...
December 31, 2021: European Respiratory Review: An Official Journal of the European Respiratory Society
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
